In this episode, Vera spoke with Carsten Rudolph, PhD, CEO of Ethris.

Ethris was founded by Dr. Rudolph and Professor Christian Plank with the goal of establishing messenger RNA (mRNA) as a novel drug modality for lung diseases such as asthma and rare pulmonary conditions like primary ciliary dyskinesia (PCD) and pulmonary alveolar proteinosis.

Ethris leverages its proprietary SNIM® RNA platform and lipidoid nanoparticle (LNP) delivery technology for versatile, multi-route therapeutic applications.

As mRNA therapies gain global traction, Dr. Rudolph sees opportunities for Ethris to make an impact.

Tune into the episode to explore the promise of nasal delivery of mRNA therapeutics as an innovative approach to treating lung diseases like asthma and beyond.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Twitter: https://twitter.com/Xtalks